Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Most non-small cell lung cancers (NSCLC) display elevated expression of epidermal growth factor receptor (EGFR), but response to EGFR kinase inhibitors is predominantly limited to NSCLC harboring EGFR-activating mutations. These mutations are associated with increased activity of survival pathways, including phosphatidylinositol 3-kinase/AKT and signal transducer and activator of transcription 3/5. We report that EGFR-activating mutations also surprisingly lead to decreased ability to activate extracellular signal-regulated kinase (ERK) compared with wild-type EGFR. In NSCLC cells and mouse embryonic fibroblasts expressing mutant EGFR, this effect on ERK correlates with decreased EGFR internalization and reduced phosphorylation of SHP2, a tyrosine phosphatase required for the full activation of ERK. We further show that ERK activation levels affect cellular response to gefitinib. NSCLC cells with EGFR mutation display reduced gefitinib sensitivity when ERK activation is augmented by expression of constitutively active mutants of mitogen-activated protein kinase/ERK kinase (MEK). Conversely, in a NSCLC cell line expressing wild-type EGFR, gefitinib treatment along with or following MEK inhibition increases death response compared with treatment with gefitinib alone. Our results show that EGFR-activating mutations may promote some survival pathways but simultaneously impair others. This multivariate alteration of the network governing cellular response to gefitinib, which we term "oncogene imbalance," portends a potentially broader ability to treat gefitinib-resistant NSCLC.
Lazzara
Matthew J
MJ
Department of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Lane
Keara
K
Chan
Richard
R
Jasper
Paul J
PJ
Yaffe
Michael B
MB
Sorger
Peter K
PK
Jacks
Tyler
T
Neel
Benjamin G
BG
Lauffenburger
Douglas A
DA
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002070:Butadienes / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066246:ErbB Receptors / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D000077156:Gefitinib; D006367:HeLa Cells; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D051379:Mice; D009154:Mutation; D009570:Nitriles / Q000494:pharmacology; D010766:Phosphorylation; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11 / Q000378:metabolism*; D011799:Quinazolines / Q000494:pharmacology*
D000970:Antineoplastic Agents; D002070:Butadienes; D004791:Enzyme Inhibitors; D009570:Nitriles; D011799:Quinazolines; C113580:U 0126; D066246:ErbB Receptors; D048049:Extracellular Signal-Regulated MAP Kinases; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11; D000077156:Gefitinib
Cancer Res. 2003 Mar 1;63(5):1130-7
12615732
Cancer Res. 2006 Aug 15;66(16):8163-71
16912195
Cell. 2006 Jun 16;125(6):1137-49
16777603
Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5
19349489
Mol Cell. 2004 Feb 13;13(3):341-55
14967142
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
15329413
Science. 2004 Aug 20;305(5687):1163-7
15284455
Cell. 2007 Jun 15;129(6):1065-79
17574021
Cancer Res. 2004 Oct 15;64(20):7241-4
15492241
Cancer Res. 2006 Jul 15;66(14):6990-7
16849543
J Biol Chem. 1990 Sep 15;265(26):15713-23
1975591
Cancer Res. 2004 Dec 15;64(24):8919-23
15604253
Lung Cancer. 2006 Oct;54(1):25-33
16872715
Cancer Sci. 2007 Dec;98(12):1817-24
17888036
Methods Enzymol. 1995;257:209-20
8583923
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5
18227510
Clin Cancer Res. 2007 May 15;13(10):2890-6
17504988
Syst Biol (Stevenage). 2006 Nov;153(6):457-66
17186707
Semin Oncol. 2002 Feb;29(1 Suppl 4):37-46
11894012
Cancer Res. 2007 May 15;67(10):4933-9
17510423
PLoS Med. 2005 Jan;2(1):e17
15696205
Nature. 2002 Jun 27;417(6892):949-54
12068308
Science. 2004 Jun 4;304(5676):1497-500
15118125
Cancer Res. 2006 Feb 15;66(4):2116-28
16489012
Cancer Cell. 2006 Nov;10(5):425-35
17097564
J Biol Chem. 2003 Mar 7;278(10):8118-25
12506122
Clin Cancer Res. 2009 May 1;15(9):3023-8
19366827
Science. 1996 Dec 20;274(5295):2086-9
8953040
Science. 2007 May 18;316(5827):1039-43
17463250
Clin Cancer Res. 2006 Dec 15;12(24):7232-41
17189394
Curr Opin Genet Dev. 2007 Feb;17(1):23-30
17227708
J Biol Chem. 2003 Oct 24;278(43):41677-84
12923167
PLoS Med. 2005 Mar;2(3):e73
15737014
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Cancer Cell. 2007 Mar;11(3):217-27
17349580
J Clin Oncol. 2007 Feb 10;25(5):587-95
17290067
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93
15731348